.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Julphar
Accenture
Teva
UBS
Merck
Covington
Chubb
Fuji
Moodys

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,983,594

« Back to Dashboard

Which drugs does patent 8,983,594 protect, and when does it expire?


Patent 8,983,594 protects ZECUITY and is included in one NDA.

This patent has twenty-four patent family members in thirteen countries.

Summary for Patent: 8,983,594

Title:Electronic control of drug delivery system
Abstract: In an exemplary embodiment, a drug delivery device for driving an electrotransport current through a body surface of a user is provided. The device includes a patch with two electrodes and one or more reservoirs storing a therapeutic agent. The one or more reservoirs release the therapeutic agent into the body surface of the user when the reservoirs are positioned over the electrodes to form an electrical path for the electrotransport current. The device includes a controller which controls a controllable power supply to drive the electrotransport current through the body surface of the user in a predetermined profile.
Inventor(s): Saar; David (Titusville, NJ), Baudis; Bogdan Mariusz (Stoneham, MA), Gupta; Rainuka (Cambridge, MA), Kamat; Vaishali Vilas (Arlington, MA), Reich; Matthew Kent (Medford, MA), Srinivasan; Rajagopalan (Cambridge, MA)
Assignee: NuPathe, Inc. (Malvern, PA)
Application Number:12/648,726
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Teva Branded Pharm
ZECUITY
sumatriptan succinate
SYSTEM;IONTOPHORESIS202278-001Jan 17, 2013DISCNYesNo► Subscribe► SubscribeY METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,983,594

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2009335085► Subscribe
Australia2015242986► Subscribe
BrazilPI0923808► Subscribe
Canada2748569► Subscribe
Canada2944660► Subscribe
China102333566► Subscribe
China104043194► Subscribe
Eurasian Patent Organization201100891► Subscribe
European Patent Office2393549► Subscribe
European Patent Office2810688► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Mallinckrodt
McKinsey
US Department of Justice
Colorcon
Healthtrust
Moodys
Johnson and Johnson
Baxter
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot